Gregory Knutson - 24 Feb 2022 Form 4 Insider Report for U.S. Stem Cell, Inc.

Role
Director
Signature
/s/ Gregory Knutson
Issuer symbol
USRM on OTC
Transactions as of
24 Feb 2022
Net transactions value
+$1,250,000,000,000
Form type
4
Filing time
04 Mar 2022, 15:01:22 UTC
Previous filing
23 Jul 2021
Next filing
25 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding USRM Common Stock 1,675,000 24 Feb 2022 Direct
holding USRM Common Stock 38,005,331 24 Feb 2022 Held by NorthStar Biotech Group, LLC of which Gregory Knutson is Managing Director

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction USRM Convertible promissory Note (right to buy) Award $1,250,000,000,000 +12,500,000 +345% $100000.00* 16,125,000 24 Feb 2022 Common Stock 12,500,000 $0.008000 Direct F1
transaction USRM Warrant Award +12,500,000 +78% 28,625,000 24 Feb 2022 Common Stock 12,500,000 $0.008000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Previously reported; By addendum the conversion price was adjusted and the maturity date extended.
F2 Issued in consideration of the extension of the extension of the maturity date.